HLB그룹, 베리스모 상장 아직…임상 1상 후 LO 추진 [현장+]

HLB Group is accelerating the development of Verismo’s KIR-CAR platform, demonstrating significant potential in treating challenging solid tumors through promising Phase 1 interim data. By securing substantial internal investment and prioritizing high-value licensing deals over immediate IPOs, the group is strategically positioning itself to lead the next generation of cell therapy.